Citi Says AppLovin Is Positioned to Meet or Beat Q3 Guidance
Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.
Already have an account? Sign in.
Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.
The non-binding bid values the rare obesity drugmaker at up to $134 a share.
Arm reported record Q2 revenue of $1.44 billion, up 27% year over year, driven by strong licensing growth and rising AI-related demand.
Record third-quarter results show AppLovin revenue up 55% to $2.18B and net income up 72% to $1.44B, alongside raised fourth-quarter guidance.
Be the first to know when deals break, stocks move, or biotech headlines hit.